Drugs / Ketorolac
Ketorolac
also known as
ketorolac tromethamine · TORADOL · Acular · Acuvail · Ketorolac Trometamol · Toradol (ketorolac) · Acular LS · Adolor · +8 more
Other / unclassified targets CDC42, PTGS2, RAC1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Omidria | — | 2015-07-28 | europa.eu ↗ |
Trials 227 · started per year
today
EU approved 2015
1
2
1
1
2
4
6
7
7
8
4
6
17
2
10
13
8
12
15
19
11
16
15
7
10
13
5
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 014 trials | ||||||
| Phase 0 | NCT07064083 | Jul → Sep 2025 overdue | — | Al-Azhar University | Recruiting | No outcome recorded |
| Phase 0 | NCT06539637 | Sep 2023 → Nov 2025 overdue | cataract | DHS Consulting | Recruiting | No outcome recorded |
| Phase 0 | NCT05756504 | Feb 2023 → Jan 2024 | acute pancreatitis | Hayatabad Medical Complex | Unknown | No outcome recorded |
| Phase 0 | NCT05336266 | Jul 2022 → Feb 2025 overdue | pancreatic ductal adenocarcinoma | Andrew Hendifar, MD | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05695664 | Aug 2021 → Jan 2022 | — | Benazir Bhutto Hospital, Rawalpindi | Completed | No outcome recorded |
| Phase 0 | NCT05019638 | Mar 2021 → May 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03817034 | Mar 2021 | — | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 0 | NCT04648540 | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT05037812 | Mar 2019 → Mar 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03820193 | Jan 2019 → Jun 2020 | substance-related disorder | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT03665753 | Nov 2018 → Sep 2019 | — | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03393364 | Apr 2018 → Jun 2020 | urinary system disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT06484439 | Feb 2018 → Nov 2021 | impacted teeth, multiple, neuropathy, painful | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT01670799 | Mar 2012 → Dec 2015 | fallopian tube cancer, ovarian cancer, peritoneum cancer | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| Phase 122 trials · 2 missed | ||||||
| Phase 1 | NCT05575999 | Jan → Oct 2026 expected | — | Kansas City Heart Rhythm Research Foundation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06911372 | Aug 2025 → Apr 2027 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT06653400 | Feb 2025 → Sep 2026 overdue | pain agnosia, uterine anomalies | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 1 | NCT06026553 | Aug 2022 → Dec 2023 | female infertility | Shady Grove Fertility Reproductive Science Center | Unknown | No outcome recorded |
| Phase 1 | NCT04941040 | Jul → Oct 2021 | supratentorial cancer | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03066115 | Dec 2020 → Dec 2021 | — | University of Wisconsin, Madison | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04505566 | Nov 2020 → Apr 2026 | diabetic retinopathy | Stephen J. Kim, MD | Completed | No outcome recorded |
| Phase 1 | NCT04353505 | Oct 2020 → Jun 2022 | cluster headache syndrome, migraine disorder, trigeminal neuralgia | Weill Medical College of Cornell University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05054868 | Apr 2020 → Jul 2024 | synostosis | Medstar Health Research Institute | Unknown | No outcome recorded |
| Phase 1 | NCT03671746 | Feb 2019 → Jun 2023 | nervous system injury | Arun Aneja | Completed | Missed primary |
| Phase 1 | NCT03767036 | Jun 2017 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02973958 | Feb 2017 → Jun 2018 | balanitis, neuropathy, painful, paraphimosis | Alberta Children's Hospital | Completed | Missed primary |
| Phase 1 | NCT02297906 | Feb 2015 → Nov 2017 | — | Columbia University | Terminated | No outcome recorded |
| Phase 1 | NCT02833207 | Apr 2012 → Nov 2021 | obesity disorder | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01609881 | Mar 2012 → Oct 2016 | — | Vanderbilt University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT01164085 | Dec 2009 → Dec 2010 | — | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT01365624 | Feb → Apr 2008 | — | American Regent, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01365650 | Dec 2007 → Feb 2008 | allergic rhinitis | Egalet Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01363076 | Jun 2007 → Jan 2008 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01363050 | Jan → Feb 2006 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01355588 | Aug → Sep 2005 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01356212 | Sep → Oct 2002 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06447194 | Oct 2025 → Jan 2027 | intervertebral disk degenerative disorder, lumbar spinal stenosis, spondylolisthesis | University of Maryland, Baltimore | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06158620 | Mar 2025 → Apr 2027 expected | ureterolithiasis, urolithiasis | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 224 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT07487246 | Jun 2026 → Apr 2027 expected | — | Rush University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06150898 | May 2025 → Apr 2027 expected | estrogen-receptor positive breast cancer | Jules Bordet Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06083571 | Jan 2024 → Dec 2025 | migraine disorder | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05842044 | Sep 2023 → Sep 2026 overdue | renal carcinoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT04646967 | Nov 2022 → Jan 2024 | balanitis, neuropathy, painful, paraphimosis | Alberta Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04291599 | Mar 2022 → Jul 2025 | acute pancreatitis | Boston Children's Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05324995 | Jan 2021 → Feb 2022 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04495894 | Aug 2020 → Feb 2024 | non-small cell lung carcinoma, renal cell carcinoma | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT03978767 | Jun 2019 → Jun 2026 | severe pre-eclampsia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03851172 | Mar → Dec 2019 | cataract | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT03818919 | Jan 2019 → Dec 2020 | rotator cuff syndrome | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2 | NCT03695367 | Oct → Nov 2018 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03111381 | Aug 2017 → Jun 2020 | nephrolithiasis | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT03669081 | Sep 2016 → Sep 2018 | neuropathy, painful | University of Utah | Completed | Met primary |
| Phase 2 | NCT02344225 | Jan 2015 → Jun 2018 | retinopathy of prematurity | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01667120 | Jul 2012 → Dec 2018 | — | Nationwide Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01498796 | Sep 2009 → May 2013 | acute tonsillitis | University of Alberta | Terminated | No outcome recorded |
| Phase 2 | NCT03693183 | Mar → Jun 2009 | dry eye syndrome | ORA, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00621530 | Mar 2008 → Jun 2013 | — | Wake Forest University | Terminated | Missed primary |
| Phase 2 | NCT00693160 | Dec 2007 → Oct 2010 | — | Wake Forest University | Terminated | No outcome recorded |
| Phase 2 | NCT00349401 | Dec 2006 → ? | — | Wake Forest University Health Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00293631 | Nov 2005 → Mar 2006 | — | POZEN | Completed | No outcome recorded |
| Phase 2 | NCT01356225 | Feb → Mar 2004 | impacted teeth, multiple | Egalet Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00001698 | Jun 1998 → Jun 2004 | leukoplakia, periodontal disorder | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT06519955 | Oct 2024 → May 2026 | developmental dysplasia of the hip | Michael C Willey | Completed | No outcome recorded |
| Phase 2/3 | NCT04939987 | Aug → Oct 2022 | — | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03825809 | Jan 2019 → Jan 2020 overdue | substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03818932 | Jan 2019 → Jan 2020 | — | Henry Ford Health System | Completed | Mixed |
| Phase 2/3 | NCT04441112 | May 2018 → Aug 2019 | osteoarthritis, hip, osteoarthritis, knee | Saint Alphonsus Regional Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT01799863 | Jun 2012 → Mar 2013 | viral conjunctivitis | Fundação Altino Ventura | Completed | No outcome recorded |
| Phase 2/3 | NCT00617097 | Jan 2008 → May 2009 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT00576329 | Nov 2006 → Oct 2007 | — | Emory University | Completed | No outcome recorded |
| Phase 338 trials · 4 met primary · 3 missed | ||||||
| Phase 3 | NCT07816302 | Oct 2026 → Mar 2027 expected | — | Tehran University of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06994442 | Dec 2025 → Jul 2029 expected | acute respiratory failure | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 3 | NCT07305883 | Dec 2025 → Jun 2026 overdue | — | Tehran University of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06968806 | Oct 2025 → Sep 2027 expected | aortic disorder | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 3 | NCT06819956 | Jun 2025 → Dec 2026 expected | — | University of Alberta | Recruiting | No outcome recorded |
| Phase 3 | NCT05992883 | Jul 2023 → Dec 2026 expected | osteoarthritis, hand | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 3 | NCT05102591 | Feb 2022 → Mar 2024 | migraine disorder | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT04528563 | May 2021 → Feb 2023 | appendicitis | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04429022 | Nov 2020 → May 2022 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT04133623 | Nov 2019 → Sep 2021 | — | IRCCS Burlo Garofolo | Completed | Missed primary |
| Phase 3 | NCT03678675 | May 2019 → Jan 2022 | pregnancy disorder | Tufts Medical Center | Completed | Met primary |
| Phase 3 | NCT04246554 | May 2019 → Oct 2020 | — | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04246541 | Apr 2019 → Sep 2021 | musculoskeletal system disorder, substance-related disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03823534 | Feb 2019 → Dec 2026 expected | bone neoplasm, plasma cell myeloma, substance-related disorder | St. Louis University | Recruiting | No outcome recorded |
| Phase 3 | NCT03967847 | Feb 2019 → Oct 2020 | rotator cuff syndrome | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03616340 | Aug 2018 → Aug 2019 | osteoarthritis, knee, rotator cuff syndrome, shoulder impingement syndrome | OSF Healthcare System | Unknown | No outcome recorded |
| Phase 3 | NCT03584373 | Jul 2018 → Mar 2022 | nephrolithiasis | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03586934 | Jun 2018 → Jun 2019 | substance-related disorder | Rush University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03485625 | Mar 2018 → Apr 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT04322968 | Jan 2018 → Jun 2019 | chronic pain syndrome, post-traumatic stress disorder | VA Ann Arbor Healthcare System | Completed | No outcome recorded |
| Phase 3 | NCT02358681 | Jun 2015 → Mar 2021 | migraine disorder | Columbia University | Completed | No outcome recorded |
| Phase 3 | NCT02465255 | Mar 2015 → Jun 2017 | — | IRCCS Burlo Garofolo | Completed | No outcome recorded |
| Phase 3 | NCT02141139 | Sep 2014 → Jan 2016 | breast neoplasm | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02540070 | Aug 2014 → Dec 2017 | osteoarthritis, knee | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 3 | NCT02568995 | May 2014 → Sep 2016 | — | Örebro University, Sweden | Completed | No outcome recorded |
| Phase 3 | NCT02361645 | Mar → Nov 2014 | hyalitis | University of Brescia | Completed | No outcome recorded |
| Phase 3 | NCT02102516 | Mar 2014 → Jun 2015 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02093689 | Feb → Aug 2014 | intraoperative floppy iris syndrome | Omeros Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01806259 | Feb 2013 → Oct 2015 | female breast carcinoma | Catholic University of Louvain | Completed | Missed primary |
| Phase 3 | NCT02266433 | Aug 2012 → Jul 2018 | de Quervain disease, epicondylitis, tenosynovitis | NYU Langone Health | Terminated | No outcome recorded |
| Phase 3 | NCT01579565 | Apr → Nov 2012 | — | Omeros Corporation | Completed | Met primary |
| Phase 3 | NCT01761071 | Jan → Nov 2012 | — | Yonsei University | Completed | No outcome recorded |
| Phase 3 | NCT01258309 | Dec 2010 → Jan 2011 | conjunctivitis, seasonal allergic rhinitis | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT00521456 | Oct 2007 → Mar 2008 | cataract | Allergan | Completed | Met primary |
| Phase 3 | NCT00524264 | Oct 2007 → Apr 2008 | cataract | Allergan | Completed | Met primary |
| Phase 3 | NCT00405262 | May 2006 → Oct 2008 | — | The Hospital for Sick Children | Completed | Missed primary |
| Phase 3 | NCT00266786 | Dec 2005 → Feb 2007 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01260883 | May 2000 → Mar 2008 | — | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 490 trials · 5 met primary · 3 missed | ||||||
| Phase 4 | NCT07840183 | Sep 2026 → Sep 2027 expected | — | Northwestern University | Recruiting | No outcome recorded |
| Phase 4 | NCT07368738 | Apr 2026 → Apr 2027 expected | — | Horizon Health Network | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07185724 | Nov 2025 → Oct 2027 expected | female infertility | Jessica D. Kresowik | Recruiting | No outcome recorded |
| Phase 4 | NCT06860711 | Jul 2025 → Jun 2028 expected | chronic kidney disease | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 4 | NCT06201676 | Feb 2025 → Dec 2026 expected | opioid abuse | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07006168 | Nov 2024 → Dec 2026 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT04895280 | Nov 2024 → Nov 2026 | rotator cuff syndrome, tendinitis | Michael Khazzam | Withdrawn | No outcome recorded |
| Phase 4 | NCT06579703 | Sep 2024 → Jul 2027 expected | sickle cell disease, vascular occlusion disorder | Children's Blood and Cancer Center at Dell Children's Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06498440 | Sep 2024 → Jul 2025 overdue | ocular hypertension, open-angle glaucoma | St. Joseph's Healthcare Hamilton | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06189781 | Dec 2023 → Dec 2026 expected | cerebral palsy, developmental dysplasia of the hip | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 4 | NCT06113497 | Nov 2023 → Oct 2024 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05664074 | Nov 2022 → Feb 2025 | acute pancreatitis | David Vitale MD | Completed | No outcome recorded |
| Phase 4 | NCT05336968 | Sep 2022 → Nov 2025 | osteoarthritis, knee | United Health Services Hospitals, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT05248984 | Jun 2022 → Nov 2023 | — | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT05190341 | Mar 2022 → Oct 2024 | female infertility | Madigan Army Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT05074056 | Feb 2022 → Dec 2024 | disorder of pharynx, obstructive sleep apnea syndrome | St. Louis University | Completed | No outcome recorded |
| Phase 4 | NCT04829799 | Feb 2022 → Aug 2023 | — | University of Florida | Withdrawn | No outcome recorded |
| Phase 4 | NCT04141319 | Dec 2021 → Jul 2022 | supratentorial cancer | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05383820 | Sep 2021 → Mar 2022 | malposition of teeth with or without hypodontia/oligodontia | University of Guadalajara | Unknown | No outcome recorded |
| Phase 4 | NCT04771156 | Sep 2021 → Mar 2027 expected | cleft lip/palate | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 4 | NCT04990804 | Aug 2021 → Feb 2022 | spinal cord disorder, substance-related disorder | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT04761302 | Apr 2021 → Oct 2022 | — | University of Puerto Rico | Completed | Mixed |
| Phase 4 | NCT04040452 | Mar 2021 → Jun 2026 overdue | congenital heart disease | Phoenix Children's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03805607 | Jan 2021 → Feb 2022 | blood coagulation disease, poisoning | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05361824 | Jan → Jun 2021 | coronary artery disorder | National Institute of Cardiovascular Diseases, Pakistan | Completed | No outcome recorded |
| Phase 4 | NCT04380298 | Dec 2020 → Jul 2021 | supratentorial cancer | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04528173 | Jul 2020 → Aug 2023 | sleep disorder, substance-related disorder, tonsillitis | Children's Hospital of Philadelphia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03535116 | Jan 2020 → Dec 2024 | — | Dr. Chandran Medical Prof Corp | Unknown | No outcome recorded |
| Phase 4 | NCT04130464 | Sep 2019 → Sep 2026 overdue | — | Ying Liu | Recruiting | No outcome recorded |
| Phase 4 | NCT03987022 | Aug 2019 → Apr 2022 | — | MetroHealth Medical Center | Completed | Missed primary |
| Phase 4 | NCT03861611 | Jul 2019 → Feb 2021 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03864133 | Jul 2019 → Jun 2021 | cataract | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT03693404 | Dec 2018 → Jun 2021 | — | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT03738904 | Oct 2018 → Aug 2022 | anus disorder | Cedars-Sinai Medical Center | Completed | Met primary |
| Phase 4 | NCT03467750 | Jul 2018 → Aug 2023 | obstructive sleep apnea syndrome | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03694821 | Jul 2018 → Jul 2019 | osteoarthritis | UConn Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03453541 | Nov 2017 → Nov 2022 | — | Albany Medical College | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03888144 | Oct 2017 → Aug 2021 | nephrolithiasis, ureterolithiasis | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03278691 | Oct 2017 → Dec 2023 | — | Henry Ford Health System | Unknown | No outcome recorded |
| Phase 4 | NCT03472872 | Sep 2017 → Jun 2020 | headache disorder | Corewell Health South | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03028012 | May 2017 → May 2019 | myofascial pain syndrome | University of Utah | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03105674 | May → Nov 2017 | anal fistula, hemorrhoid, ulcer of anus and rectum | Columbia University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04115644 | May → Sep 2017 | rotator cuff syndrome | Michael Khazzam | Terminated | No outcome recorded |
| Phase 4 | NCT02958566 | Jan → Dec 2017 | colon carcinoma, constipation disorder, diverticulitis of colon, paralytic ileus +1 | University of Illinois College of Medicine at Peoria | Unknown | No outcome recorded |
| Phase 4 | NCT02829944 | Nov 2016 → Mar 2019 | — | Duke University | Completed | Missed primary |
| Phase 4 | NCT02885441 | Sep 2016 → Feb 2019 | acute pancreatitis | Ilam University of Medical Sciences | Terminated | No outcome recorded |
| Phase 4 | NCT03727048 | Aug 2016 → Mar 2018 | — | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| Phase 4 | NCT02509312 | May 2016 → Oct 2017 | blood coagulation disease, poisoning, substance-related disorder | University Hospitals Cleveland Medical Center | Completed | Missed primary |
| Phase 4 | NCT02867176 | Jan → Jul 2016 | — | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| Phase 4 | NCT02612272 | Nov 2015 → Oct 2017 | osteoarthritis, knee | St. Luke's Hospital, Pennsylvania | Unknown | No outcome recorded |
| Phase 4 | NCT02604537 | Oct 2015 → Oct 2024 | de Quervain disease | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02570503 | Oct 2015 → Feb 2021 | osteoarthritis, knee | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 4 | NCT02571283 | Oct 2015 → May 2016 | — | University of Louisville | Withdrawn | No outcome recorded |
| Phase 4 | NCT02474654 | Jul 2015 → Jan 2019 | — | Health Sciences North Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02653742 | May 2015 → Dec 2022 | neuropathy, painful, otitis media | Anica Crnkovic | Unknown | No outcome recorded |
| Phase 4 | NCT02380898 | Mar → Sep 2015 | — | Assiut University | Completed | Met primary |
| Phase 4 | NCT02729285 | Jul → Oct 2014 | — | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT03031795 | Jul 2014 → Mar 2016 | — | OhioHealth | Completed | Met primary |
| Phase 4 | NCT02078492 | Mar 2014 → Dec 2015 | — | Antonios Likourezos | Completed | No outcome recorded |
| Phase 4 | NCT01807234 | Feb 2013 → Dec 2014 | migraine disorder | Johns Hopkins University | Completed | Met primary |
| Phase 4 | NCT02060604 | Dec 2012 → Jan 2014 | wet macular degeneration | University of Brescia | Completed | No outcome recorded |
| Phase 4 | NCT01736358 | Oct 2012 → Jun 2014 | urolithiasis | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01898052 | Oct 2012 → Feb 2014 | — | Thammasat University | Completed | No outcome recorded |
| Phase 4 | NCT01514175 | Jan → Dec 2012 | chronic pain syndrome | Culpeper Surgery Center | Unknown | No outcome recorded |
| Phase 4 | NCT01534806 | Jan 2012 | migraine disorder | Akron Children's Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01374828 | Jan 2012 → Dec 2013 | — | The Cleveland Clinic | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT01490931 | Nov 2011 → Aug 2012 | — | Hersh, Elliot V., DMD, MS, PhD | Completed | No outcome recorded |
| Phase 4 | NCT01291472 | Jun → Sep 2011 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01304212 | Apr 2011 → Feb 2014 | — | Jose Antonio Bernia Gil | Completed | No outcome recorded |
| Phase 4 | NCT01859585 | Mar 2011 → Jan 2013 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 4 | NCT01560767 | Oct 2010 → Jul 2011 | osteoarthritis, knee | University of Warwick | Completed | No outcome recorded |
| Phase 4 | NCT01345162 | Mar 2010 → May 2012 | — | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| Phase 4 | NCT01281891 | Sep 2009 → Sep 2012 | osteoarthritis, hip | Region Örebro County | Unknown | No outcome recorded |
| Phase 4 | NCT00981435 | Sep 2009 → Sep 2015 | glaucoma | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00865540 | Mar 2009 → Aug 2011 | cataract | Clinica Oftamologica Zona Sul | Unknown | No outcome recorded |
| Phase 4 | NCT01832311 | Jan 2009 → Dec 2011 | cataract, type 2 diabetes mellitus | University of Zagreb | Completed | No outcome recorded |
| Phase 4 | NCT00765232 | Oct 2008 → Nov 2010 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00765128 | Oct 2008 → Nov 2010 | nephrolithiasis | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00774540 | Aug 2008 → Sep 2014 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00901628 | Apr 2008 → Mar 2009 | osteoarthritis, knee | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00562627 | Nov 2007 → Jun 2009 | osteoarthritis, knee | Asker & Baerum Hospital | Completed | Met primary |
| Phase 4 | NCT00366691 | Feb 2006 → Sep 2007 | cataract | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 4 | NCT00347204 | Jan → Jun 2006 | hyperopia, myopia | Center For Excellence In Eye Care | Completed | No outcome recorded |
| Phase 4 | NCT00289419 | Feb 2005 → Feb 2006 | osteoarthritis, hip | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00161577 | Jan 2004 → Jun 2006 | — | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT00348582 | — | cataract | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00348244 | — | cataract | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00347503 | — | cataract | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00433225 | — | macular retinal edema | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00377546 | — | — | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable29 trials · 2 met primary · 1 missed | ||||||
| — | NCT07141589 | Aug 2024 → Nov 2025 overdue | — | Cairo University | Recruiting | No outcome recorded |
| — | NCT06112548 | Mar 2024 → Nov 2025 | osteoarthritis, knee | Damascus University | Completed | No outcome recorded |
| — | NCT06307106 | Jan → Oct 2024 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT06608056 | Jan → Jun 2024 | — | Pakistan Air Force (PAF) Hospital Islamabad | Completed | No outcome recorded |
| — | NCT05908851 | Nov 2023 → Nov 2024 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| — | NCT05489796 | Jun → Aug 2022 | — | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT05206110 | Apr 2022 → Sep 2024 | — | Jessa Hospital | Completed | No outcome recorded |
| — | NCT06630520 | Mar → Jun 2022 | — | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| — | NCT05189704 | Dec 2021 → Feb 2023 | — | Seoul National University Hospital | Unknown | Met primary |
| — | NCT05994287 | Jan 2021 → Jan 2022 | — | Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty | Completed | No outcome recorded |
| — | NCT04483427 | Sep 2020 → Jul 2022 | obstructive sleep apnea syndrome | Bahaa Mohammed Refaie | Unknown | No outcome recorded |
| — | NCT05393414 | Nov 2019 → Mar 2020 | — | University of Puerto Rico | Completed | No outcome recorded |
| — | NCT04176783 | Mar 2018 → Jul 2021 | — | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| — | NCT05248724 | Aug 2017 → Sep 2020 | — | Castilla-La Mancha Health Service | Completed | No outcome recorded |
| — | NCT02700451 | Mar 2016 → Dec 2021 | lumbar disk disease, osteoarthritis, spine, spinal stenosis, spondylosis | Hospital for Special Surgery, New York | Completed | Met primary |
| — | NCT03116672 | Feb 2016 → Feb 2017 | pulpitis | Universidad Autonoma de Baja California | Completed | No outcome recorded |
| — | NCT02470299 | Oct 2015 → Oct 2018 | fallopian tube cancer, ovarian cancer, peritoneum cancer | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| — | NCT02937896 | Jan 2015 → Feb 2016 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| — | NCT03402100 | Oct 2014 → Dec 2019 | drug pseudoallergy, myopia | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT01836406 | Dec 2012 → Jun 2013 | renal cell carcinoma | Yonsei University | Completed | No outcome recorded |
| — | NCT01664559 | Jul 2012 → Mar 2014 | — | Lynn Ngo | Completed | Missed primary |
| — | NCT01576276 | Apr 2012 → Feb 2017 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01471639 | Nov 2011 → Jun 2012 | — | The Cleveland Clinic | Completed | No outcome recorded |
| — | NCT01595282 | Jun 2011 → Jun 2012 | — | Planned Parenthood League of Massachusetts | Completed | No outcome recorded |
| — | NCT01133639 | May 2010 → Feb 2012 | toe, misshapen | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01081535 | May 2009 → Feb 2010 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT00956462 | Jul 2007 → Dec 2009 | glaucoma | University Health Network, Toronto | Unknown | No outcome recorded |
| — | NCT01513564 | Jan 2001 → Dec 2003 | spondylolisthesis | Northern Orthopaedic Division, Denmark | Completed | No outcome recorded |
| — | NCT01449448 | Sep 2000 → Sep 2005 | bursitis, shoulder impingement syndrome | Madigan Army Medical Center | Withdrawn | No outcome recorded |
| Comparator or background therapy219 trials | ||||||
| Phase 0 | NCT06081101 Comparator | Mar 2025 → Jul 2028 expected | arthritis, sacroiliac | McMaster University | Recruiting | No outcome recorded |
| Phase 0 | NCT06462573 Background | Sep 2024 → Sep 2026 overdue | ureterolithiasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT03638999 Comparator | Jul 2018 → Oct 2026 expected | urolithiasis | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05062356 Background | Nov 2021 → Aug 2024 | chronic pain syndrome | St. Mary's Research Center, Canada | Completed | No outcome recorded |
| Phase 1 | NCT02400645 Comparator | Mar 2015 → May 2016 | — | University of Tennessee | Terminated | No outcome recorded |
| Show all 219 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2022-11-01 | Alembic Pharmaceuticals Ltd. | Regulatory 3rd November, 2022, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals announces its second injectable product approval from its General Sterile Facility - Final Approval for Ketorolac Tromethamine Injection USP. |
| 2019-11-04 | Omeros Corporation | Results Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain omeros.com ↗
Patients in the OMIDRIA group were 6.7 times more likely not to require fentanyl, with 9.8 percent of OMIDRIA patients requiring fentanyl versus 42.1 percent of epinephrine patients (P = 0.006). |
| 2019-05-07 | Omeros Corporation | Results Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting omeros.com ↗
Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids |
| 2018-10-01 | Omeros Corporation | Regulatory Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA® omeros.com ↗
CMS’ Separate Payment for Cataract Surgery Drug Resumes Today |
| 2018-04-19 | Omeros Corporation | Results Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting omeros.com ↗
Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C. , April 13-17, 2018 . |
| 2017-12-12 | Omeros Corporation | Regulatory Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients omeros.com ↗
FDA approved the sNDA for OMIDRIA under priority review. |
| 2016-11-21 | Omeros Corporation | Results Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial omeros.com ↗
In the trial, OMIDRIA was safe and well tolerated with adverse event rates consistent with those seen in pediatric cataract surgery and similar in the OMIDRIA and phenylephrine groups. |
| 2016-01-15 | Omeros Corporation | Results Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference omeros.com ↗
the use of Omidria across a wide range of patients, including those with non-complex cataracts, complex cataracts, intraoperative floppy iris syndrome (IFIS) and/or pseudoexfoliation, has resulted in statistically significant: |
All press releases naming this drug 11 releases
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 453 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ketorolac | “The purpose of this study is to compare the effectiveness of the NSAID ketorolac tromethamine ophthalmic solution 0.4% with the steroid loteprednol etabonate ophthalmic...” NCT00366691 ↗445“The pain cocktail includes three medications: ropivacaine (a local anesthetic), ketorolac (an anti-inflammatory medication), and epinephrine (a medication to constrict blood...” NCT04074265 ↗ “The NSAID group will receive 30 mg of intravenous (IV) ketorolac (Ketorolac 30 mg/ml dose vial, NDC 00409-3795-01; manufacturer: Hospira) administered up to two hours prior to...” NCT01789216 ↗ “Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that has an analgesic efficacy similar to commonly used opioids, and that recently has found wide acceptance in the...” NCT05194904 ↗ “Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon...” NCT02563587 ↗ “Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made...” NCT01667445 ↗ “A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the...” NCT02682498 ↗ “Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium...” NCT01579565 ↗ “The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30...” NCT02502877 ↗ “Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium...” NCT02093689 ↗ “Following assessment of eligibility and documentation of consent to participate in the study, participants will be randomized to receive intraoperative Ketorolac Tromethamine...” NCT03111381 ↗ |
| Known as | Acular | “"5％ Ketorolac Tromethamine" , " Acular® " spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm...” NCT02608788 ↗2“plus Ketorolac tromethamine 0.5% (Acular®, Allergan), one drop three times/day” NCT00992355 ↗ “topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)” NCT01761071 ↗ |
| Known as | Acular LS | “ketorolac (Acular LS)” NCT00347204 ↗ |
| Known as | Acuvail | “PURPOSE: To evaluate the efficacy and safety of twice-daily, preservative-free ketorolac 0.45% (Acuvail; Allergan, Inc, Irvine, California, USA) administration for treatment of...” PMID 21145532 ↗ Dec 20101“Eyes were randomized to ketorolac tromethamine, 0.45% (Acuvail), or placebo 4 times daily for 3 days before pars plana vitrectomy.” PMID 24336915 ↗ Jan 2014 |
| Known as | Adolor | “Adolor ( ketorolac) 15\_30 mg IV every 6 hours up to 5 days post-operation” NCT07032883 ↗ |
| Known as | Dolac | “The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.” NCT02867176 ↗ |
| Known as | IV-K | “Intravenous Ketorolac (IV-K)” NCT06994442 ↗ |
| Known as | Kelac | “Ketorolac (Kelac) 0.5% ophthlmic solution” NCT01769352 ↗ |
| Known as | ketorolac acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00707421 ↗ |
| Known as | Ketorolac Injectable Solution | “Drug: Ketorolac Injectable Solution” NCT02953210 ↗ |
| Known as | Ketorolac Trometamol | “Ketorolac Trometamol 5 mg/ml eye drops, solution” NCT00405730 ↗1“Ketorolac Trometamol 30Mg/1mL Injection” NCT03638999 ↗ |
| Known as | ketorolac tromethamine | “This group receives Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at...” NCT03453541 ↗32“TORADOL (ketorolac tromethamine), is a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe...” NCT03669081 ↗ “PURPOSE: To evaluate whether adding perioperative topical ketorolac tromethamine 0.4% improves cataract surgery outcomes relative to topical steroids alone in patients without...” PMID 18599019 ↗ Jul 2008 “Following assessment of eligibility and documentation of consent to participate in the study, participants will be randomized to receive intraoperative Ketorolac Tromethamine...” NCT03111381 ↗ “"5％ Ketorolac Tromethamine" , " Acular® " spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm...” NCT02608788 ↗ “Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that is extensively used for the management of renal colic in the emergency department (ED).” PMID 33370510 ↗ Feb 2021 “Ketorolac tromethamine (Toradol) is a parenteral, nonsteroidal anti-inflammatory drug that has been used extensively to provide postoperative analgesia.” NCT01498796 ↗ “Once the microcatheter is in a good position, 15 mg Dexamethasone Sodium Phosphate and 15 mg of Ketorolac Tromethamine will be infused over 30 minutes.” NCT04353505 ↗ “olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.” NCT01258309 ↗ “Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%” NCT00595543 ↗ “Eyes were randomized to ketorolac tromethamine, 0.45% (Acuvail), or placebo 4 times daily for 3 days before pars plana vitrectomy.” PMID 24336915 ↗ Jan 2014 |
| Known as | Ketorolac/Toradol (NDC 00409-3795-01; manufacturer: Hospira) | “Ketorolac/Toradol (NDC 00409-3795-01; manufacturer: Hospira)” NCT01789216 ↗ |
| Known as | SPRIX | “SPRIX(intranasal ketorolac tromethamine)” NCT02102516 ↗ |
| Known as | SPRIX(R) | “Efficacy and tolerability of intranasal ketorolac (SPRIX(R)) was assessed in abdominal surgery patients.” PMID 20557145 ↗ Aug 2010 |
| Known as | TORADOL | “Following assessment of eligibility and documentation of consent to participate in the study, participants will be randomized to receive intraoperative Ketorolac Tromethamine...” NCT03111381 ↗12“To determine if Celebrex (Celecoxib) is as effective as Toradol (Ketorolac) at controlling postoperative pain when given in addition to standard postoperative pain control regimens.” NCT03331315 ↗ “Other pain medicines, like acetaminophen (also called Tylenol) and ketorolac (also called Toradol), are available but aren't commonly used because we don't know if they help.” NCT06994442 ↗ “Multimodal local injection of bupivacaine (Marcaine), morphine sulfate (Duramorph), ketorolac (Toradol) given at the fracture site at the time of hip fracture surgery” PMID 37199438 ↗ Sep 2023 “Ketorolac tromethamine (Toradol) is a parenteral, nonsteroidal anti-inflammatory drug that has been used extensively to provide postoperative analgesia.” NCT01498796 ↗ “Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.” NCT03319784 ↗ “Among NSAIDS, Ketorolac tromethamine (Toradol) is the first approved for parenteral use in 1990 in the United States.” NCT05074056 ↗ “IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval.” NCT06026553 ↗ “Topical ketorolac tromethamine {TORADOL, Nonsteroidal Anti-inflammatory}” NCT06539637 ↗ “Toradol is a type of brand name. We will be using the generic version.” NCT03535116 ↗ “30 mg Toradol/ketorolac (30mg/ml)” NCT07151417 ↗ |
| Known as | Toradol (ketorolac) | “Toradol (ketorolac)” NCT05037812 ↗1“Toradol (ketorolac)” NCT05019638 ↗ |
| Action | Inhibit | “Ketorolac is a 7-fold selective inhibitor of cyclooxygenase-2 (Cox-2)” NCT00001698 ↗ |
| Modality | Other / unclassified | “a non steroidal anti-inflammatory drug (ketorolac)” NCT01281891 ↗ |
| Route | Oral | “ketorolac tromethamine oral rinse” NCT00001698 ↗ |
| Target | CDC42 | “time-dependent inhibition of Rac1 and Cdc42 GTPase activity” NCT02470299 ↗ |
| Target | RAC1 | “time-dependent inhibition of Rac1 and Cdc42 GTPase activity” NCT02470299 ↗ |